VivoSim Labs financials
$0.2025−8.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 |
|---|---|---|---|---|---|
| Revenue | $18.0K | $40.0K | $26.0K | $28.0K | $37.0K |
| Gross profit | $18.0K | $40.0K | $26.0K | $28.0K | $37.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$2.8M | -$3.2M | -$2.8M | -$2.6M | -$2.9M |
| Net income | -$1.3M | -$5.8M | -$2.7M | -$2.5M | -$2.8M |
| Net margin | −7433.3% | −14410.0% | −10350.0% | −9089.3% | −7683.8% |
| Diluted EPS | $-0.25 | $-2.19 | $-1.03 | $-0.98 | $-1.14 |
| EBITDA | -$2.7M | -$3.1M | -$2.7M | -$2.6M | -$2.9M |
| Operating cash flow | -$3.2M | -$2.2M | -$2.3M | -$2.4M | -$3.9M |
| Free cash flow | -$3.2M | -$2.2M | -$2.3M | -$2.4M | -$3.9M |
| Diluted shares | 5.2M | 2.6M | 2.6M | 2.6M | 2.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.7M | $5.0M | $4.3M | $6.7M | $9.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $3.8M | $7.4M | $7.0M | $9.7M | $12.0M |
| Total liabilities | $6.2M | $8.5M | $2.5M | $2.6M | $2.4M |
| Shareholders' equity | -$2.3M | -$1.1M | $4.4M | $7.1M | $9.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology